Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 1Phase 2 Interventional Results available

Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

ClinicalTrials.gov ID: NCT00555048

Public ClinicalTrials.gov record NCT00555048. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective Trial to Evaluate the Role of In Vivo T Cell Depletion by Campath® (Alemtuzumab) in Reduction of Transplant Related Mortality in Transplantation From HLA-Class I or Class II Mismatched, Unrelated Donors

Study identification

NCT ID
NCT00555048
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Fred Hutchinson Cancer Center
Other
Enrollment
1 participant

Conditions and interventions

Interventions

  • alemtuzumab Biological
  • busulfan Drug
  • cyclophosphamide Drug
  • methotrexate Drug
  • tacrolimus Drug
  • allogeneic hematopoietic stem cell transplantation Procedure
  • peripheral blood stem cell transplantation Procedure

Biological · Drug · Procedure

Eligibility (public fields only)

Age range
Up to 50 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2007
Primary completion
Sep 30, 2010
Completion
Not listed
Last update posted
May 23, 2017

Started 2007

United States locations

U.S. sites
2
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Fred Hutchinson Cancer Research Center Seattle Washington 98104-1024
Seattle Cancer Care Alliance Seattle Washington 98109-1023

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00555048, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 23, 2017 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00555048 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →